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Background: N-terminal pro-brain natriuretic peptide (NT-ProBNP) has emerged as an
important marker of cardiac stress and may reflect the severity of underlying cardiac
dysfunction, which is thought to be associated with obstructive sleep apnoea syndrome
(OSAS).
Methods: This study evaluated the plasma concentration of NT-ProBNP in 60 consecutive
patients (median age 55.7 years, median body mass index (BMI) 31.8) who were referred to
a sleep laboratory with a suspicion of OSAS. Each subject underwent measurement of
morning NT-ProBNP plasma levels, polysomnography and echocardiography. Patients were
treated with nasal continuous or bilevel positive airway pressure ventilation (nCPAP/BIPAP)
or without mechanical respiratory support, depending on clinical symptoms and results of
polysomnography. Three months after treatment of OSAS 28 of the patients were
reassessed for re-evaluation of NT-ProBNP and polysomnography.
Results: Low or high levels of NT-proBNP were not associated with AHI and other sleep
related indices (p40.3). There was no correlation between NT-proBNP and AHI or other
sleep related indices. In multiple regression analysis, NT-proBNP was significantly
correlated with left ventricular ejection fraction, creatinine clearance and the presence
of systemic arterial hypertension but not with AHI.Published by Elsevier Ltd.
597 1278; fax: +49 431 597 1302.
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NT-proBNP and obstructive sleep apnoea 135Conclusions: Our results show by a robust multiple regression analysis, that NT-pro BNP is
not associated with OSAS and NT-pro BNP cannot be used as a sensitive marker for
underlying cardiovascular abnormalities in patients with OSAS.
& 2007 Published by Elsevier Ltd.Introduction
Obstructive sleep apnoea syndrome (OSAS) is a common
disorder with an estimated prevalence of at least 2–4%
among middle aged adults.1 There has been a growing
interest in potential relationships between OSAS and brain
natriuretic peptide (BNP) regulation.2–6
BNP is a hormone which is synthesized predominantly by
myocytes of the left ventricle in response to wall disten-
sion.7 It is synthesized as a prohormone (ProBNP) that upon
secretion is cleaved into a biologically active peptide
BNP and an N-terminal proBNP fragment (NT-proBNP). NT-
ProBNP is preferred as a more sensitive diagnostic measure
of BNP secretion, because it has a relatively long half-life
and is stable in whole blood samples.8–10
BNP has been extensively studied in patients with cardiac
disease and elevated levels have been associated with
diminished left ventricular functional capacity and a poor
prognosis among such patients.11–15 OSAS is associated with
coronary heart diseases, heart failure and cardiac arrhyth-
mias. It has been suggested that OSAS causes an increased
ventricular load and therefore ventricular distension during
periods of apnoea.16,17 Therefore it is tempting to propose
that BNP could serve as a prognostic and risk marker in
patients with OSAS.
In previous studies the role of natriuretic peptides in OSAS
has been controversial.2–6 Conclusions are difficult to make
because patient groups have been too small or subclass
differences were not well considered. It is known that BNP is
strongly influenced by confounders like gender, creatinine
clearance, age, adiposity, left ventricular function and other
coexisting diseases.18–21 According to this, we elucidated
the value of NT-ProBNP in patients with OSAS considering
potentially confounding variables.
Methods
Patients and study design
Patients who were referred to our sleep laboratory with
excessive snoring, a suspicion of OSAS or excessive daytime
somnolence were consecutively included in this study. Males
or females were eligible for the study if they were 421
years old. Exclusion criteria included refusal to participate
in the study, shift workers, a preceding diagnosis of OSAS,
psychiatric causes of sleep disorder, central sleep apnoea or
Cheyne-Stokes respiration on polysomnography (420%
events) and the use of sedatives and muscle relaxants.
Altogether 60 patients with a median age of 55.7 years
(inter quartile range: 43–62) and a body mass index (BMI) of
31.8 kg/m2 (28–38) were included.
All patients referred to the sleep laboratory had current
pulmonary function tests and electrocardiogram. Lungfunction parameters included forced vital capacity (FVC)
and forced expiratory volume in 1 s (FEV1). Each parameter
was calculated as percent of predicted.
Each patient received a standard echocardiograph in our
clinic. Echocardiographic images were obtained in the long
axis, short axis, apical two-chamber, four-chamber, and
subcostal views. All measurements were made under
standardized resting conditions with the subjects in the
supine position after a minimum rest period of 5min in a
quiet, darkened examination room. The left ventricular
internal end-diastolic dimension (LVDd), left ventricular
internal systolic dimension (LVDs), left ventricular posterior
wall thickness (LVPWT) and interventricular septal thickness
(IVST) were measured manually. End-diastole was defined by
the onset of the QRS complex. Left ventricular mass
(LVmass) was estimated according to the method of
DEVEREUX and REICHEK22 and LVmass was corrected for
body surface area (LVmass index) in order to adjust for
differences in cardiac size due to variations in body size.
Left ventricular ejection fraction (LVEF) was calculated from
LVDd and LVDs. The sonographer was blinded to the results of
the polysomnography and NT-ProBNP levels.
Chest X-ray was performed when the patient was over 45
years old and the last chest X-ray was imaged greater than one
year ago. Previously clinical variables were collected from
case notes and questionnaires completed during assessments.
These comprised pretreatment demographic variables (age,
sex, BMI, current cigarette smoking status, history of
preexisting diseases and current drug usage). Daytime
systemic blood pressure was measured in the right upper
arm using an automatic oscillometric device after at least
10min periods of rest with the subjects in the seated position
and the mean blood pressure was used for subsequent
analyses. The epworth sleepiness scale (ESS) was used to
investigate changes in subjective daytime sleepiness.23 Blood
samples for evaluation of serum NT-ProBNP and creatinine
levels were taken directly after polysomnography between
6.00 a.m. and 6.30 a.m. None of the subjects reported
significant strenuous physical activity within a period of 72 h
before testing. All blood samples were taken following of a
rest period for at least 20min and in the supine position. The
creatinine clearance was calculated using the formula derived
by COCKCROFT and GAULT.24
All patients underwent an overnight standard polysomno-
graphy in the sleep laboratory. A second polysomnography
was subsequently performed to determine the appropriate
continuous or bilevel positive airway pressure (nCPAP or
BIPAP) in those patients who were deemed eligible for
treatment depending on clinical symptoms and result of
diagnostic polysomnography. For nCPAP treatment either
SOMNOcomfort (Weinmann, Hamburg, Germany) or Mini MAX
(MAP, Martinsried, Germany) were used, while for BIPAP
therapy only SOMNOvent S (Weinmann) was used. Thirty-six
patients were treated with nCPAP, seven patients were
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ular advancement device. Twenty-nine of these patients
were readmitted after 3–4 months of treatment to our sleep
laboratory for re-evaluation with polysomnography and
measurement of NT-ProBNP level. Seventeen of the 44
patients had removed or discontinued nCPAP therapy due to
discomfort. Compliance with prescribed nCPAP/BIPAP ther-
apy was based on the actual hours of usage as registered by
an integrated hour meter.
The study was approved by the ethics committee of the
Schleswig-Holstein University, Campus Kiel. Informed con-
sent was obtained from all patients.
Polysomnography
All patients underwent overnight polysomnography in the
sleep laboratory. All variables were recorded on a commer-
cially available computer system (CNS SleepLab, Jaeger and
Toennies, Hoechburg, Germany) and included (1) electro-
encephalography (C4/A1, C3/A2 of the international 10–20
system), (2) bilateral electrooculography, (3) submental
electromyography, (4) thoracic and abdominal movements
measured by uncalibrated inductive plethysmography, (5)
saturation of oxyhaemoglobin (SaO2) using a finger oxymeter,
(6) air flow through the nose and mouth recorded by
thermistors, (7) electrocardiography, (8) snoring microphone
and (9) video monitoring using an infrared video camera. The
entire recording was supervised by a technician.
Polysomnography records were scored in 30 s periods for
sleep, breathing and oxygenation. According to the com-
monly used clinical criteria25: obstructive apnoeas were
defined as a complete cessation of oronasal airflow forX10 s
in the presence of chest-wall motion, hypopnoeas were
defined as a reduction in respiratory airflow of X50% of the
airflow or a clear reduction in airflow associated with more
than 3% arterial oxygen desaturation or an arousal, both
events lasting X10 s. The average number of apnoeas and
hypopnoeas per hour of sleep were calculated as the apnea
hypopnea index (AHI). OSAS was diagnosed when AHI was
X5/h. Sleep was staged manually using the methods of
RECHTSCHAFFEN and KALES as described.26
Serum NT-ProBNP measurements
Blood samples (EDTA plasma) for NT-ProBNP measurements
were immediately centrifuged at 1800 g for 20min at 0 1C.
Plasma concentrations of NT-proBNP were measured by a
sandwich immunoassay on an Elecsys 2010 (Roche Diagnos-
tics, Mannheim, Germany) as previously described.27 The
analytical range extended from 5 to 35,000 pg/ml and the
total coefficient of variation was below 0.061 in pooled
human plasma samples. The NT-proBNP levels were mea-
sured by a technician who was blinded to the results of the
polysomnography. We defined a normal NT-proBNP level for
men o85 pg/ml, and for woman o155 pg/ml according to
previously described criteria.28
Statistical analysis
Data of patients were sorted into two groups above and
below the medians of primary endpoints NT-ProBNP and AHI.Basic characteristics of patients were compared using w2
test for categorical characteristics and Wilcoxon for all
other tests. For correlation analysis Spearman test was
performed. To identify independent predictors of NT-
ProBNP, a multiple linear regression model was used. NT-
ProBNP was set as the continuous dependent variable and
AHI and significant or trend towards significant (po0.09)
characteristics from univariate analyses (age, sex, LVEF,
LVmass index, creatinine clearance and systemic arterial
hypertension, Table 1) were entered as independent
variables. In a second multiple linear regression model AHI
was set as dependent variable and NT-proBNP and significant
or trend towards significant (po0.09) characteristics from
univariate analyses (BMI, minimal SaO2, mean SaO2 and ESS,
Table 2) were selected as independent variables. The results
of the linear regression analysis are represented after
backward selection (likelihood-ratio criteria). The regres-
sion coefficients were calculated according to Wald test.
One observation was assumed to be an outlier and was
excluded from correlations analysis and multiple linear
regression models because these analyses are sensitive
against particular isolated realizations. For all tests, the
level of significance was set to 5%. Group values
are presented by median values with 25th and 75th
percentile for continuous variables, and proportions with
95% confidence interval for binary response. Statistical
analysis was performed by Matlab, The MathWorks, Inc.,
Version 5.3.Results
Patients characteristics and NT-ProBNP values
Patients were subdivided into two groups above and below
the median of NT-ProBNP or AHI. The plasma levels of NT-
proBNP ranged from 5pg/ml (the lowest detectable value)
to 665 pg/ml with a median of 42.1 pg/ml and AHI ranged
from 0 to 107/h with a median of 22.4/h from all patients at
first presentation. Baseline characteristics for NT-ProBNP
and AHI groups are shown in Tables 1 and 2. Increased levels
of NT-proBNP were found more frequently in female
(po0.01), older age groups (po0.01) and in patients with
impaired LVEF (po0.001), higher LVmass index (po0.001),
impaired creatinine clearance (po0.001) and known sys-
temic arterial hypertension (po0.05). Low or high levels of
NT-proBNP were not associated with AHI and other sleep
related indices (ESS, minimal SaO2, mean SaO2, Table 1).
High baseline AHI levels were significantly associated with
BMI (po0.01), minimal SaO2 (po0.001), mean SaO2
(po0.01) with a trend towards higher ESS (p ¼ 0.07). Low
or high levels of AHI were not associated with NT-proBNP
(Table 2). One female 41-year-old patient (M.F.) presented
an extraordinary high level of NT-ProBNP level (665 pg/ml)
that was outlying from all other observations. This obese
patient (BMI 37.6 g/m2) had a known history of systemic
arterial hypertension, echocardiography revealed a ventri-
cular hypertrophy without an impairment of function and
polysomnography showed a severe obstructive sleep apnoea
syndrome (RDI 107/h). This patient was excluded from
correlation analysis and multiple linear regression models
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Table 1 Baseline patients characteristics according to baseline NT-proBNP level.
Below median
NT-ProBNP group (n ¼ 30)
Above median
NT-ProBNP group (n ¼ 30)
p-Value
NT-Pro BNP (pg/ml) 22 (10–29) 86 (53–160) o0.001y
AHI (events/h) 29 (6–55) 20 (7–48) n.s.y
Female no (%)z 7 (23) 18 (60,0) o0.01y
Age (year) 52 (39–58) 60 (48–64) o0.01y
Body mass index (kg/m2) 32 (28–38) 31 (27–37) n.s.y
ESS (points) 12 (6–15) 10 (5–12) n.s.y
Minimal SaO2 (%)
 87 (86–89) 87 (84–89) n.s.y
Mean SaO2 (%)
 93 (91–94) 93 (91–95) n.s.y
Mean systolic blood pressure (mmHg) 97 (93–103) 100 (93–109) n.s.y
LVEF (%) 59 (58–62) 53 (51–57) o0.001y
LVmass index (g/m2) 109 (96–127) 143 (107–164) o0.01y
FEV1 (%)
 97 (88–103) 90 (74–102) n.s.y
FVC (%) 95 (85–99) 90 (75–103) n.s.y
Creatinine clearance (ml/min) 150 (132–198) 105 (95–136) o0.001y
Smoking n (%)z 11 (37) 11 (37) n.s.y
Diabetes mellitus n (%)z 3 (10) 3 (10) n.s.y
Coronary diseases n (%)z 5 (17) 2 (7) n.s.y
Systemic arterial hypertension n (%)z 13 (43) 23 (77) o0.05y
Results expressed as median (25–75th percentile).
yWilcoxon test.
zResults expressed as number (percentage).
yChi-square test. NT-proBNP, N-terminal pro-brain natriuretic peptide; AHI, apnea hypopnea index; ESS, Epworth sleepiness scale;
LVEF, left ventricular ejection fraction; LV, mass index left ventricular mass corrected for body surface area; FEV1, forced expiratory
volume in 1 s; FVC, forced expiratory vital capacity. n.s. not significant.
Table 2 Baseline patients characteristics according to baseline AHI.
Below median AHI
group (n ¼ 30)
Above median AHI
group (n ¼ 30)
p-Value
AHI (events/h) 7 (2–18) 48 (34–72) o0.001y
NT-ProBNP (pg/ml) 46 (24–90) 32 (20–86) n.s.y
Female no (%)z 15 (50) 10 (33) n.s.y
Age (year) 58 (43–63) 55 (42–62) n.s.y
Body mass index (kg/m2) 29 (27–32) 35 (30–40) o0.01y
ESS (points) 9 (4–13) 12 (9–15) 0.07y
Minimal SaO2 (%)
 89 (88–91) 86 (83–87) o0.001y
Mean SaO2 (%)
 94 (93–95) 92 (87–94) o0.01y
Mean systolic blood pressure (mmHg) 98 (93–105) 98 (93–107) n.s.y
LVEF (%) 57 (52–61) 57 (52–60) n.s.y
LVmass index (g/m2) 114 (101–149) 120 (98–157) n.s.y
FEV1 (%)
 92 (80–106) 94 (84–101) n.s.y
FVC (%) 95 (77–105) 92 (83–100) n.s.y
Creatinine clearance (ml/min) 108 (96–167) 145 (108–176) n.s.y
Smoking n (%)z 13 (43) 9 (30) n.s.y
Diabetes mellitus n (%)z 3 (10) 3 (10) n.s.y
Coronary diseases n (%)z 3 (10) 4 (13) n.s.y
Systemic arterial hypertension n (%)z 15 (50) 21 (70) n.s.y
Results expressed as median (25–75th percentile).
yWilcoxon test.
zResults expressed as number (percentage).
yChi-square test. NT-proBNP, N-terminal pro-brain natriuretic peptide; AHI, apnea hypopnea index; ESS, Epworth sleepiness scale;
LVEF, left ventricular ejection fraction; LV, mass index left ventricular mass corrected for body surface area; FEV1, forced expiratory
volume in 1 s; FVC, forced expiratory vital capacity. n.s. not significant.
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isolated realizations.
Correlations of NT-proBNP
No significant correlation was identified between NT-proBNP
and AHI (r ¼ 0.03, Figure 1A), ESS (r ¼ 0.10, Figure 1B),
minimal SaO2 (r ¼ 0.09, Figure 1C) and mean SaO2
(r ¼ 0.03, Figure 1D). There was a significant correlation
between NT-proBNP and creatinine clearance (r ¼ 0.5,
po0.001, Figure 1E), age (r ¼ 0.4, po0.001, Figure 1F),
LVmass index (r ¼ 0.4, po0.01, Figure 1G), and LVEF
(r ¼ 0.4, po0.01, Figure 1(H).
Multiple regression models of NT-proBNP and AHI
To determine whether NT-proBNP or AHI was influenced by
confounders, a stepwise multiple regression model was used
with either NT-proBNP or AHI as the dependent variable. For
NT-proBNP-model, AHI and significant determinants (Table 1)
such as age, sex, LVEF, LVmass index, creatinine clearance and
systemic arterial hypertension were used as independent
variables. Analogously, for AHI model, NT-proBNP and sig-
nificant determinants (Table 3) such as BMI, minimal SaO2,
mean SaO2 and ESS were selected as independent variables.
The NT-proBNP-model model (R2 ¼ 0.46) identified LVEF
(b ¼ 0.38, po0.001), creatinine clearance (b ¼ 0.48,
po0.001), and systemic arterial hypertension (b ¼ 0.21,
po0.05) as significantly correlated with NT-proBNP levels
(Table 2). The AHI model regression model (R2 ¼ 0.277)
identified BMI (b ¼ 0.28, po0.01) and minimal SaO2
(b ¼ 0.39, po0.01) as the only significant independent
predictors of AHI (Table 4). In both models there was no
association between AHI and NT-proBNP levels.
Effect of nCPAP therapy
Twenty-nine patients, who were treated with nCPAP or BIPAP
therapy were re-examined after a follow-up of 106 (92–136)
days. The integrated hour meter showed a regular use of
nCPAP/BIPAP therapy for all patients. One patient was
diagnosed with acute pulmonary embolism 4 weeks before
reassessment and was subsequently excluded from further
analysis. With regard to the other 28 subjects there were no
changes in health status or medications during the period of
treatment. Treatment with nCPAP significantly decreased AHI
(po0.001, Figure 2A) and ESS (11 (6–15) to 5 (3–8), po0.001,
data not shown) and increased the mean SaO2 (91.4% (89–93)
to 94.1% (93–95); po0.001, data not shown). nCPAP therapy
did not significantly alter NT-proBNP levels (Figure 2B) during
the follow-up period. At initial examination seven of those 28
patients presented pathologically elevated NT-proBNP levels
and sex of this subgroup demonstrated a reduction in
NT-proBNP levels following nCPAP treatment.
Discussion
Our results show that NT-proBNP is not associated with
obstructive sleep apnoea syndrome by four major findings:
(1) low or high levels of NT-proBNP were not associated withAHI and other sleep related indices, (2) AHI did not correlate
with NT-proBNP, (3) NT-proBNP was only related to
LV-function, systemic arterial hypertension and creatinine
clearance and not to AHI and other sleep related indices and
(4) treatment with nCPAP did not change NT-proBNP levels
significantly.
In several studies it has already been shown that OSAS and
cardiovascular diseases are strongly associated suggesting
OSAS as a probable independent risk factor for systemic
arterial hypertension and other cardiovascular dis-
eases.16,17,29,30 Obstructive apnoeas are accompanied by
hypoxemia, CO2 retention and arousals which activate the
sympathetic nervous system and cause repetitive surges in
heart rate and blood pressure.31 Moreover, permanent
exaggerated negative intrathoracic pressure against an
occluded upper airway markedly increases LV afterload
during sleep, and all these together may stimulate myocyte
growth and promote cardiac hypertrophy.32 Accordingly, a
large population based study identified OSAS as an indepen-
dent risk factor for heart failure.33 Although it was not a
primary goal of our study, we found high incidences of
systemic arterial hypertension and ventricular hypertrophy
in patients with obstructive sleep apnoea. However, these
results need careful interpretation because patients in this
study may have more co-morbidity than the general
population and therefore not reflect a representative
sample, albeit patients were randomly selected and
included in this study consecutively as they presented to
the clinic.
BNP is a cardiac neurohormone which is secreted
predominantly by ventricular myocytes under the influence
of ventricular volume expansion, pressure overload and
myocardial hypoxemia.8,34 Several studies have shown that
BNP or NH2-terminal portion proBNP (NT-proBNP) is in-
creased in different cardiac diseases such as heart failure,
different stages of coronary heart disease and cardiac
hypertrophy.18–20,35 BNP has been utilized for diagnostic
purposes to distinguish patients with cardiac diseases from
those who present with dyspnea from some other causes.36
There were also findings that BNP is a valuable prognostic
marker in cardiac patients, since it has been suggested that
elevated levels of this hormone were associated with higher
rates of hospital admissions, overall mortality and sudden
death.37 These observations are in agreement with our
study. We found baseline NT-proBNP levels significantly
increased in patients with impaired LVEF, higher LVmass
according to body surface area and known systemic arterial
hypertension in medical history. After robust statistical
analysis with a multiple regression model, a significant
correlation between NT-proBNP and both LVEF and systemic
arterial hypertension was identified. Interestingly, LVmass
index did not correlate significantly with NT-proBNP, which
suggests a weaker association than between LVEF and
systemic arterial hypertension with NT-proBNP. In contrast,
NT-proBNP was not significantly associated with coronary
heart disease, which may be due to the low numbers of
patients in this study or to undetected preclinical coronary
heart disease in some patients.
There are some studies addressing circulating BNP levels in
patients with OSAS.2–6 However, conclusions about the role of
NT-proBNP are difficult to make, because (1) most of these
studies did not sufficiently consider confounding factors such
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Figure 1 Correlation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in 60 consecutive patients with a suspicion of OSAS.
(A) Correlation between NT-proBNP and apnoe-hypnoe index (AHI); r ¼ 0.03, p ¼ not significant (n.s.). (B) Correlation between
NT-proBNP and Epworth sleepiness scale (ESS); r ¼ 0.10, p ¼ n.s. (C) Correlation between NT-proBNP and minimal saturation of
oxyhaemoglobin (SaO2); r ¼ 0.09, p ¼ n.s. (D) Correlation between NT-proBNP and mean SaO2; r ¼ 0.03, p ¼ n.s. (E) Correlation
between NT-proBNP and creatinine clearance; r ¼ 0.5, po0.001. (F) Correlation between NT-proBNP and age; r ¼ 0.4, po0.001.
(G) Correlation between NT-proBNP and left ventricular mass corrected for body surface area (LVmass index); r ¼ 0.4, po0.01.
(H) Correlation between NT-proBNP and left ventricular ejection fraction (LVEF); r ¼ 0.4, po0.01. * Excluded from analysis.
NT-proBNP and obstructive sleep apnoea 139as obesity, age, creatine clearance, sex or cardiovascular
disease, all of which influence NT-proBNP and OSAS, (2) study
groups were small or (3) only a selected study subgroup wereincluded. For example, Kita and coworkers3 found BNP levels
elevated in patients with severe OSAS during sleep, however
cardiovascular disease was not considered and the study group
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Table 3 Stepwise multiple regression models for N-terminal pro-brain natriuretic peptide.
R2 Independent variables b 95% Confidence interval p-Value
0.460 LVEF 0.381 5.67/1.56 o0.001
Creatinine clearance 0.476 0.75/0.31 o0.001
Systemic arterial hypertension 0.214 1.59/49.27 o0.05
95% Confidence interval expressed in (minimum)/(maximum).
Initial independent variables: apnoea-hypopnoea index, age, sex, left ventricular ejection fraction (LVEF), left ventricular mass
index, creatinine clearance, systemic arterial hypertension.
Table 4 Stepwise multiple regression models for apnoe-hypopnoe index.
R2 Independent variables b 95% Confidence interval p-Value
0.277 Body mass index 0.217 0.13/1.57 0.09
Minimal SaO2 0.390 4.65/0.97 o0.01
95% Confidence interval expressed in (minimum)/(maximum).
Initial independent variables: N-terminal pro-brain natriuretic peptide, body mass index, minimal saturation of oxyhemoglobin
(SaO2), mean saturation of oxyhemoglobin, Epworth sleepiness scale.
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Figure 2 Comparison of patients with obstructive sleep apnoea syndrome before and after treatment. Twenty-eight patients were
reassessed 3 months after treatment of OSAS for re-evaluation of N-terminal pro-brain natriuretic peptide (NT-proBNP) and
polysomnography. (A) Apnoe-hypopnoe index (AHI). (B) NT-ProBNP.
R.-H. Hu¨bner et al.140was small (n ¼ 14). Moller and coworkers4 who reported BNP
levels in patients with OSAS mildly but not significantly
elevated, had excluded diseases of the heart, lungs, kidneys
and endocrine organs but had not considered other confound-
ing factors such as age, obesity or sex. Recently, Svatikova and
coworkers,2 Tasci and coworkers5 and Vartany and coworkers6
suggested, in agreement with our data, that BNP levels are
not elevated in patients with OSAS compared to a healthy
control group, but here control groups were either not
matched to age and sex or confounders like obesity were
not considered.To our knowledge we were the first to perform a robust
statistical multivariate analysis to adjust for most confound-
ing factors. After regarding most contributing confounding
factors in our study (for AHI: BMI, mean and minimal SaO2,
ESS; for BMI: age, sex, LVEF, LVmass index, creatinine
clearance, systemic arterial hypertension), we showed that
NT-pro BNP levels in blood were not associated with OSAS.
The strong independent association between NT-proBNP
with higher age, female sex and impaired renal function
assessed by creatinine clearance are in agreement with
previously reported results.18,19 It was suggested that
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NT-proBNP and obstructive sleep apnoea 141association of female gender and BNP may be related to
hormonal status because BNP levels were found to be higher
in woman using hormone replacement therapy.38 The strong
association between BNP and age independent of cardio-
vascular or renal disease has been demonstrated in other
studies.19,39 Although data is limited, it is assumed that
alterations in BNP production, secretion or degradation
occurs with age.39 The association with impaired renal
function is already well known and probably caused by
impaired clearance of natriuretic peptides in these pa-
tients.40 It has recently been shown in a large population-
based cohort that obesity, as indexed by elevated BMI, has
an inverse relationship with BNP concentration, whereby it
is unknown whether obesity either suppresses synthesis or
release from cardiomyocytes or increases clearance of
natriuretic peptides.41 Interestingly, we did not observe
any relationship between NT-proBNP and BMI in our patients.
However, conclusions are difficult to draw because of the
strong confounder between OSAS and obesity.
Our results suggest that NT-proBNP is not sensitive to
detect myocardial stress caused by OSAS. In agreement to
this observation, we did not see a change of NT-proBNP in
the total patient population, which is partly in agreement
with other studies.2,5 We observed an interesting longterm
lowering effect of NT-proBNP levels by nCPAP therapy in six
patients with pathological elevated levels before treatment
suggesting an improvement of cardiovascular function due
to nCPAP therapy. However, this observation was not
statistically significant probably due to the small subset
group. This is in agreement with findings that effective OSAS
treatment by CPAP in patients with coexisting heart failure
improved LV-function and reduced systolic blood pressure.16
However the effect of nCPAP treatment with regard to
natriuretic peptides remains controversial and needs
careful interpretation due to the possible role of other
confounding variables.
In conclusion, the study shows by a robust multiple
regression analysis, that NT-pro BNP is not associated with
OSAS and NT-pro BNP cannot be used as a sensitive marker
for underlying preclinical cardiovascular changes in patients
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